Clinical Application of Two Neoadjuvant Chemotherapy Regimens in the Treatment of Cervical Cancer

WANG Ning; ZHANG Xue-ying; SHAO Ting

doi:10.14033/j.cnki.cfmr.2016.16.017

Abstract：Objective:To explore the efficacy and safety of neoadjuvant chemotherapy in the treatment ofⅠb2~Ⅱb stage cervical cancer.Method:66 cervical cancer patients with neoadjuvant chemotherapy treatment for cervical cancer before operation in our hospital from January 2010 to December 2013 were analyzed retrospectively,according to the chemotherapy plan,they were divided into two groups,34 cases of PF group(cisplatin+5-fluorouracil),32 cases of PIB group(cisplatin+ifosfamide+bleomycin).All patients received the radical hysterectomy of cervical cancer after 14 days.Result:The tumor volume of PF group after chemotherapy was better than that of PIB group,the difference was statistically significant(P<0.05);the serum squamous cell carcinoma antigen(SCC) in PF group was significantly higher than that in group PIB(P<0.05);the incidence of adverse reactions in group PF was lower than that in group PIB(P<0.05);two groups of patients with operation time,intraoperative bleeding,vaginal resection margin positive,lymph node metastasis were compared,there were no statistically significant differences(P>0.05).Conclusion:Cervical cancer neoadjuvant chemotherapy can effectively control cervical lesions, improve the quality of surgery, improve the treatment efficiency.Cisplatin+5-PF solution tumor volume reduction and SCC decreased compared with the PIB program more ideal, less adverse reaction,it is the ideal cervical cancer neoadjuvant chemotherapy.